According to Chung et al. [31], IL-17A mediates paracrine network to promote tumor resistance to anti-angiogenic therapy by inducing the expression of GM-CSF (through NFκB and ERK signaling) to mobilize and recruit MDSCs to the tumor microenvironment. This evidence concerns the gene IL17A and neoplasm.